Huyut, ZubeyirBakan, NuriAkbay, Halil IbrahimYildirim, SerkanSekeroglu, Mehmet Ramazan2025-05-102025-05-1020221381-34551744-416010.1080/13813455.2020.17671492-s2.0-85085490942https://doi.org/10.1080/13813455.2020.1767149https://hdl.handle.net/20.500.14720/5985Objective: This study investigated effect of zaprinast and avanafil on vascular endothelial growth factor (VEGF), bone morphogenic protein (BMP) 4 and 7, and vitamin D-3 levels against the negative effect of dexamethazone. Method: Rats were randomly divided into four groups (n = 6). Control: Empty a syringe was immersed and removed subcutaneously. Dexamethasone (DEX): 120 mu g/kg DEX was injected subcutaneously once a day for 28 days. DEX + zaprinast and DEX + avanafil groups: 10 mg/kg zaprinast and avanafil were administrated to rats in addition to the same procedure in the DEX, respectively. VitaminD(3), VEGF, BMP4 and 7 levels by enzyme linked immunosorbent assay (ELISA) and angiogenesis by histopathological/immunohistochemical were evaluated. Results: BMP4 values in the DEX were lower than the other groups (p < .05). DEX + zaprinast and DEX + avanafil exhibited an increase in all the parameters compared to the control and DEX (p < .05). However, these were not significant for the DEX + zaprinast (p > .05). Also, there was a significant increase in angiogenesis in the DEX + zaprinast and DEX + avanafil. Conclusion: Zaprinast and significantly avanafil induced vitamin D-3, BMP4 and 7 levels by increasing angiogenesis in renal.eninfo:eu-repo/semantics/closedAccessAngiogenesisPhosphodiesterase-5 InhibitorDexamethasoneBone Morphogenetic ProteinVitamin D3Article1285Q2Q21290129632421396WOS:000535345700001